Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

NCT05322733 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

DRUG: Orelabrutinib
DRUG: Obinutuzumab
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

The First Affiliated Hospital with Nanjing Medical University